Get the Stockscreener App
7.42
15.10%
-1.32
After Hours:
7.42
Aligos Therapeutics Inc stock is traded at $7.42, with a volume of 181.52K.
It is down -15.10% in the last 24 hours and down -1.98% over the past month.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
See More
Previous Close:
$8.74
Open:
$7.54
24h Volume:
181.52K
Relative Volume:
3.31
Market Cap:
$45.91M
Revenue:
$2.19M
Net Income/Loss:
$-24.19M
P/E Ratio:
-0.8626
EPS:
-8.6017
Net Cash Flow:
$-82.94M
1W Performance:
-7.13%
1M Performance:
-1.98%
6M Performance:
-28.52%
1Y Performance:
+57.20%
1-Day Range:
$7.18
$8.20
1-Week Range:
$7.18
$8.97
52-Week Range:
$4.20
$13.69
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
7.42 | 54.08M | 2.19M | -24.19M | -82.94M | -8.6017 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Resumed | Jefferies | Buy |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Responsive Playbooks and the ALGS Inflection - Stock Traders Daily
Aligos Therapeutics (ALGS) Updates on Phase 2 Hepatitis B Study Results - GuruFocus
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Aligos Advances HBV Candidate With Interim Data, Fast Track - TipRanks
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation - Investing News Network
Aligos receives FDA fast track designation for hepatitis B drug - Investing.com
Aligos Reports DSMB OK to Expand HBeAg- Cohort; FDA Grants Fast Track for Pevifoscorvir - TradingView — Track All Markets
Aligos receives FDA fast track designation for hepatitis B drug By Investing.com - Investing.com Canada
Aligos Therapeutics (ALGS) wins FDA Fast Track as HBV trial advances - Stock Titan
Aligos Therapeutics announces first interim analysis results from the phase 2 B-Supreme study of pevifoscorvir sodium in participants with chronic hepatitis B virus infection and grant of FDA fast track designation - marketscreener.com
Aligos Therapeutics Announces First Interim Analysis Results From The Phase 2 B-Supreme Study Of Pevifoscorvir Sodium In Participants With Chronic Hepatitis B Virus Infection And Grant Of FDA Fast Track Designation - TradingView — Track All Markets
Hepatitis B study avoids futility as FDA grants fast-track status - Stock Titan
Total debt per share of Aligos Therapeutics, Inc. – MUN:5WK0 - TradingView — Track All Markets
Aug Mood: Can Aligos Therapeutics Inc continue delivering strong returnsCEO Change & Safe Entry Point Alerts - baoquankhu1.vn
Understanding the Setup: (ALGS) and Scalable Risk - Stock Traders Daily
ALGS.O PE Ratio & Valuation, Is ALGS.O Overvalued - Intellectia AI
ALGS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Tangible book value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Net current asset value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Decliners Report: What are Aligos Therapeutics Incs technical support levels2026 Snapshot & Daily Volume Surge Signals - baoquankhu1.vn
Cash per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
Book value per share of Aligos Therapeutics, Inc. – DUS:5WK0 - TradingView
ALGS PE Ratio & Valuation, Is ALGS Overvalued - Intellectia AI
If You Invested $1,000 in Fractyl Health (GUTS) - Stock Titan
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average PT from Analysts - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Raised to Strong-Buy at Jefferies Financial Group - Defense World
Earnings Risk: Can Aligos Therapeutics Inc continue delivering strong returns2026 Action & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
WestPark Capital initiates coverage of Aligos Therapeutics (ALGS) with buy recommendation - MSN
Insider Sell: Will Aligos Therapeutics Inc outperform its industry peers2026 Trends & Low Drawdown Investment Ideas - baoquankhu1.vn
Bull Run: What analysts say about Aligos Therapeutics Inc stockWeekly Profit Summary & AI Forecasted Entry/Exit Points - baoquankhu1.vn
The Technical Signals Behind (ALGS) That Institutions Follow - Stock Traders Daily
Aug PostEarnings: Will Aligos Therapeutics Inc outperform its industry peers2026 News Drivers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Aligos Therapeutics (ALGS) 8th Annual MASH Investor Conference Summary - Quartr
If You Invested $1,000 in Aligos Therapeutics, Inc. (ALGS) - Stock Titan
ALGS Technical Analysis & Stock Price Forecast - intellectia.ai
Activity Recap: Can Aligos Therapeutics Inc weather a recessionTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
Jefferies Lowers Price Target for Aligos Therapeutics (ALGS) to $48 | ALGS Stock News - GuruFocus
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential - Investing.com India
Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential By Investing.com - Investing.com South Africa
Nikhil Aneja Net Worth (2026) - GuruFocus
What is HC Wainwright’s Estimate for ALGS Q1 Earnings? - Defense World
Precision Trading with Aligos Therapeutics Inc. (ALGS) Risk Zones - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Aligos Therapeutics (ALGS), Demant (WILLF) - The Globe and Mail
Aligos Therapeutics (ALGS) officer awarded 23,310 stock options at $7.03 strike - Stock Titan
Aligos Therapeutics (ALGS) accounting officer granted 9,450 stock options at $7.03 - Stock Titan
Aligos Therapeutics (ALGS) awards 37,485 stock options to officer Calhoun - Stock Titan
Aligos Therapeutics (ALGS) CEO granted stock options for 105,840 shares - Stock Titan
HC Wainwright & Co. Reiterates Buy Rating on ALGS with $50 Price Target | ALGS Stock News - GuruFocus
Dip Buying: Can Aligos Therapeutics Inc weather a recessionWeekly Earnings Recap & Risk Managed Trade Strategies - baoquankhu1.vn
Aligos Therapeutics (NASDAQ:ALGS) Rating Lowered to Sell at Wall Street Zen - Defense World
Aug Highlights: Can Aligos Therapeutics Inc weather a recessionMarket Rally & Daily Entry Point Alerts - baoquankhu1.vn
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):